{"id":"bendroflumethiazide","rwe":[],"tags":[{"label":"Thiazide Diuretic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 12 member 3","category":"target"},{"label":"SLC12A3","category":"gene"},{"label":"KCNMA1","category":"gene"},{"label":"CA1","category":"gene"},{"label":"C03AA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Approved 1950s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"},{"label":"Sodium Chloride Symporter Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":555.826,"date":"","count":138,"signal":"Cardiospasm","source":"DrugCentral FAERS","actionTaken":"Reported 138 times (LLR=556)"},{"llr":533.437,"date":"","count":137,"signal":"Palmoplantar keratoderma","source":"DrugCentral FAERS","actionTaken":"Reported 137 times (LLR=533)"},{"llr":524.654,"date":"","count":248,"signal":"Lip swelling","source":"DrugCentral FAERS","actionTaken":"Reported 248 times (LLR=525)"},{"llr":504.221,"date":"","count":137,"signal":"Pruritus genital","source":"DrugCentral FAERS","actionTaken":"Reported 137 times (LLR=504)"},{"llr":494.571,"date":"","count":136,"signal":"Sleep terror","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=495)"},{"llr":489.173,"date":"","count":149,"signal":"Tension headache","source":"DrugCentral FAERS","actionTaken":"Reported 149 times (LLR=489)"},{"llr":460.523,"date":"","count":141,"signal":"Atrial tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 141 times (LLR=461)"},{"llr":434.228,"date":"","count":137,"signal":"Carotid artery occlusion","source":"DrugCentral FAERS","actionTaken":"Reported 137 times (LLR=434)"},{"llr":404.607,"date":"","count":138,"signal":"Anosmia","source":"DrugCentral FAERS","actionTaken":"Reported 138 times (LLR=405)"},{"llr":371.101,"date":"","count":337,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 337 times (LLR=371)"},{"llr":371.074,"date":"","count":138,"signal":"Facial pain","source":"DrugCentral FAERS","actionTaken":"Reported 138 times (LLR=371)"},{"llr":362.825,"date":"","count":90,"signal":"Immunisation","source":"DrugCentral FAERS","actionTaken":"Reported 90 times (LLR=363)"},{"llr":356.853,"date":"","count":142,"signal":"Pain of skin","source":"DrugCentral FAERS","actionTaken":"Reported 142 times (LLR=357)"},{"llr":340.473,"date":"","count":155,"signal":"Subarachnoid haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 155 times (LLR=340)"},{"llr":318.341,"date":"","count":147,"signal":"Eye pruritus","source":"DrugCentral FAERS","actionTaken":"Reported 147 times (LLR=318)"}],"drugInteractions":[{"url":"/drug/dofetilide","drug":"dofetilide","action":"Avoid combination","effect":"May interact with Dofetilide","source":"DrugCentral","drugSlug":"dofetilide"},{"url":"/drug/lithium","drug":"lithium","action":"Avoid combination","effect":"May interact with Lithium","source":"DrugCentral","drugSlug":"lithium"}],"commonSideEffects":[{"effect":"Bradycardia (heart rate <60 bpm)","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Peripheral vascular insufficiency (Raynaud type)","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dizziness or fatigue","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Cardiac failure","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Rhythm/conduction disturbances","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Abdominal discomfort","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Indigestion","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Bloating","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Dry mouth, eyes, or skin","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Impotence or decreased libido","drugRate":"0.5%","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Acute pancreatitis","Anaphylaxis","Anuria","Bronchospasm","Cardiogenic shock","Complete atrioventricular block","Decompensated cardiac failure","Depressive disorder","Diabetes mellitus","Disease of liver","Gout","Hepatic coma","Hypercalcemia","Hypercholesterolemia","Hyperparathyroidism","Hyperuricemia","Hypokalemia","Hypomagnesemia","Hyponatremia","Kidney disease","Myasthenia gravis","Neonatal hyperbilirubinemia","Oliguria","Partial atrioventricular block"],"specialPopulations":{"Pregnancy":"Use only if the potential benefit justifies the potential risk","Geriatric use":"Dose selection should be cautious, usually starting at the low end of the dosing range","Paediatric use":"Safety and effectiveness not established"},"seriousAdverseEvents":[{"effect":"Symptomatic bradycardia (heart rate <40 bpm)","drugRate":"2%","severity":"serious"},{"effect":"First degree heart block","drugRate":"0.1%","severity":"serious"},{"effect":"Third degree heart block","drugRate":"0.1%","severity":"serious"},{"effect":"Bronchospasm","drugRate":"0.1%","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"0.1%","severity":"serious"},{"effect":"Thrombocytopenic or nonthrombocytopenic purpura","drugRate":"0.1%","severity":"serious"},{"effect":"Mesenteric arterial thrombosis","drugRate":"0.1%","severity":"serious"},{"effect":"Ischemic colitis","drugRate":"0.1%","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"0.1%","severity":"serious"},{"effect":"Anaphylactic reactions","drugRate":"0.1%","severity":"serious"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BENDROFLUMETHIAZIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:45:42.932514+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:45:53.762802+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BENDROFLUMETHIAZIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:45:54.079259+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thiazide-sensitive sodium-chloride cotransporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:45:55.152282+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1684/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:45:54.801897+00:00"}},"allNames":"corzide","offLabel":[],"synonyms":["bendroflumethiazide","bendrofluazide","benzhydroflumethiazide","benzidroflumetiazide","benzydroflumethiazide","benzylhydroflumethiazide","benzylrodiuran"],"timeline":[{"date":"1959-12-07","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Corzide (BENDROFLUMETHIAZIDE) is a thiazide diuretic medication originally developed by, currently owned by. It targets the solute carrier family 12 member 3 and is a small molecule modality. FDA approved in 1959 for the treatment of hypertensive disorder, Corzide is off-patent with no active Orange Book patents. As a generic medication, it is manufactured by multiple companies. Key safety considerations include monitoring of electrolyte levels and potential side effects such as hypokalemia.","brandName":"Corzide","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Solute carrier family 12 member 3","novelty":"Follow-on","targets":[{"gene":"SLC12A3","source":"DrugCentral","target":"Solute carrier family 12 member 3","protein":"Solute carrier family 12 member 3"},{"gene":"KCNMA1","source":"DrugCentral","target":"Calcium-activated potassium channel subunit alpha-1","protein":"Calcium-activated potassium channel subunit alpha-1"},{"gene":"CA1","source":"DrugCentral","target":"Carbonic anhydrase 1","protein":"Carbonic anhydrase 1"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA4","source":"DrugCentral","target":"Carbonic anhydrase 4","protein":"Carbonic anhydrase 4"}],"modality":"Small Molecule","drugClass":"Thiazide Diuretic","explanation":"","oneSentence":"","technicalDetail":"Corzide (BENDROFLUMETHIAZIDE) acts as a competitive inhibitor of the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the kidneys, leading to increased sodium and chloride excretion and subsequent diuresis."},"commercial":{"launchDate":"1959","_launchSource":"DrugCentral (FDA 1959-12-07, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/305","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BENDROFLUMETHIAZIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BENDROFLUMETHIAZIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:58:25.146251","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:45:56.596417+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"hydroflumethiazide","drugSlug":"hydroflumethiazide","fdaApproval":"1959-07-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydrochlorothiazide","drugSlug":"hydrochlorothiazide","fdaApproval":"1959-02-12","patentExpiry":"Jan 23, 2044","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"chlorothiazide","drugSlug":"chlorothiazide","fdaApproval":"1958-09-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"polythiazide","drugSlug":"polythiazide","fdaApproval":"1961-09-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"trichlormethiazide","drugSlug":"trichlormethiazide","fdaApproval":"1960-03-09","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methylclothiazide","drugSlug":"methylclothiazide","fdaApproval":"1960-10-21","relationship":"same-class"},{"drugName":"cyclothiazide","drugSlug":"cyclothiazide","fdaApproval":"1982-06-08","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"bendroflumethiazide","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"hydroflumethiazide","brandName":"hydroflumethiazide","genericName":"hydroflumethiazide","approvalYear":"1959","relationship":"same-class"},{"drugId":"hydrochlorothiazide","brandName":"hydrochlorothiazide","genericName":"hydrochlorothiazide","approvalYear":"1959","relationship":"same-class"},{"drugId":"chlorothiazide","brandName":"chlorothiazide","genericName":"chlorothiazide","approvalYear":"1958","relationship":"same-class"},{"drugId":"polythiazide","brandName":"polythiazide","genericName":"polythiazide","approvalYear":"1961","relationship":"same-class"},{"drugId":"trichlormethiazide","brandName":"trichlormethiazide","genericName":"trichlormethiazide","approvalYear":"1960","relationship":"same-class"},{"drugId":"methylclothiazide","brandName":"methylclothiazide","genericName":"methylclothiazide","approvalYear":"1960","relationship":"same-class"},{"drugId":"cyclothiazide","brandName":"cyclothiazide","genericName":"cyclothiazide","approvalYear":"1982","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05753059","phase":"PHASE1","title":"Mechanisms of Diuretic Resistance in Heart Failure, Aim 2","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-08-10","conditions":["Heart Failure"],"enrollment":50,"completionDate":"2027-06"},{"nctId":"NCT06209359","phase":"PHASE1","title":"Mechanisms of Diuretic Resistance in Heart Failure, Aim 3","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-07-24","conditions":["Heart Failure","Diuretic Resistance"],"enrollment":50,"completionDate":"2028-03-01"},{"nctId":"NCT00648297","phase":"PHASE1","title":"Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-08","conditions":["Healthy"],"enrollment":42,"completionDate":"2006-08"},{"nctId":"NCT00647660","phase":"PHASE1","title":"Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-07","conditions":["Healthy"],"enrollment":66,"completionDate":"2006-08"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT02235402","phase":"PHASE4","title":"A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1997-12","conditions":["Hypertension"],"enrollment":26,"completionDate":""},{"nctId":"NCT00518479","phase":"NA","title":"Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2003-09","conditions":["Hypertension","Left Ventricular Hypertrophy"],"enrollment":42,"completionDate":"2004-04"},{"nctId":"NCT00429897","phase":"NA","title":"Double Blind Crossover Comparison of Diuretics in the Young","status":"UNKNOWN","sponsor":"University of Cambridge","startDate":"2006-08","conditions":["Low-Renin Hypertension"],"enrollment":30,"completionDate":"2007-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Nadolol and Bendroflumethiazide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000145992","MMSL":"3020","NDDF":"002297","UNII":"5Q52X6ICJI","VUID":"4017612","CHEBI":"CHEBI:59243","VANDF":"4017612","INN_ID":"994","RXNORM":"1369","UMLSCUI":"C0004975","chemblId":"CHEMBL1684","ChEMBL_ID":"CHEMBL1684","KEGG_DRUG":"D00650","DRUGBANK_ID":"DB00436","PUBCHEM_CID":"2315","SNOMEDCT_US":"387520007","IUPHAR_LIGAND_ID":"7122","MESH_DESCRIPTOR_UI":"D001539"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"90%"},"publicationCount":369,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C03AA01","allCodes":["C03AA01","C03AB01","C03EA13"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1959","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:45:56.596417+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}